4,771 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2020 / Unblinded controlled pilot trial
Forty patients receiving palliative chemotherapy were placed unblinded into a treatment group (n = 29, receiving 15 daily capsules of pulverized broccoli sprouts) or placebo group (n = 11, receiving methylcellulose) for up to 1 year. The mean death rate was lower in the treatment group in the first 6 months (day 30: 0% vs 18%, day 90: 0% vs 25%, day 180: 25% vs 43%), but the endpoint at day 180 was not statistically significant (p = 0.291). Dropout rates after 1 year were high (72% treatment, 55% placebo). Taking 15 daily capsules was difficult for some patients, and the sprouts sometimes increased digestive problems, nausea, and emesis.
Lozanovski VJ, Polychronidis G, Gross W, et al. Invest New Drugs, 2020. PMID 31250356
2020 / Randomized controlled trial (secondary analysis)
In a secondary analysis of a factorial randomized trial involving 3,365 adults followed for 22.3 years, smoking was associated with increased risk of gastric cancer incidence (OR, 1.72; 95% CI, 1.003-2.93) and mortality (HR, 2.01; 95% CI, 1.01-3.98). Garlic supplementation was associated with reduced gastric cancer mortality exclusively among individuals who never drank alcohol (HR, 0.33; 95% CI, 0.15-0.75; interaction P = .03). No significant interactions occurred between vitamin supplementation and lifestyle behaviors.
Guo Y, Li ZX, Zhang JY, et al. JAMA Netw Open, 2020. PMID 32589229
2019 / Randomized controlled trial
During 22 years of follow-up in 3,365 residents, garlic supplementation for 7.3 years significantly reduced gastric cancer mortality (hazard ratio 0.66, 95% CI 0.43 to 1.00), though it did not significantly reduce incidence (odds ratio 0.81, 95% CI 0.57 to 1.13). Vitamin supplementation significantly lowered both gastric cancer mortality (hazard ratio 0.48, 95% CI 0.31 to 0.75) and incidence (odds ratio 0.64, 95% CI 0.46 to 0.91).
Li WQ, Zhang JY, Ma JL, et al. BMJ, 2019. PMID 31511230
2018 / Randomized crossover trial
In this randomized crossover pilot trial with 34 patients undergoing chemotherapy for gynecological cancer, 60-hour fasting (36 hours before to 24 hours after treatment) was compared to a normocaloric diet. Fasting reduced chemotherapy-related declines in quality of life to below the minimally important difference. Deterioration of total FACIT-F scores was lower during fasted cycles compared to non-fasted cycles in both groups without serious adverse events.
Bauersfeld SP, Kessler CS, Wischnewsky M, et al. BMC Cancer, 2018. PMID 29699509
2018 / Randomized controlled trial
In a secondary analysis of a randomized trial among 48,835 postmenopausal women, 1,764 developed incident breast cancer during an 8.5-year dietary intervention. Post-diagnosis follow-up showed significantly higher overall survival in the low-fat dietary group compared with usual diet (10-year survival 82% vs 78%; HR, 0.78; 95% CI, 0.65-0.94; P = 0.01). The dietary group had fewer cardiovascular deaths (HR, 0.62; 95% CI, 0.39-0.99) and non-significant reductions in breast cancer mortality.
Chlebowski RT, Aragaki AK, Anderson GL, et al. JAMA Oncol, 2018. PMID 29800122
2017 / Randomized controlled trial
Eligible breast cancer patients receiving doxorubicin-based chemotherapy were randomized to an 8-week intervention with high daily onion intake (100 to 160 g/d) or low daily onion intake (30 to 40 g/d). Analyses of 23 participants per group revealed that high onion intake significantly decreased fasting blood glucose and insulin levels relative to low onion intake (P < .001). Post-treatment insulin resistance assessed by HOMA-IR was also significantly lower in the high onion group (P < .05).
Jafarpour-Sadegh F, Montazeri V, Adili A, et al. Integr Cancer Ther, 2017. PMID 27352956
2017 / Randomized controlled trial
In a randomized trial, 166 patients receiving pelvic radiotherapy were assigned to low-fiber, habitual-fiber, or high-fiber dietary counseling. Although the primary endpoint of start-to-nadir bowel score changes did not differ significantly between groups (P = 0.093), high-fiber advice led to smaller score reductions from start to end of radiotherapy (-3.7 ± 12.8 vs -10.8 ± 13.5; P = 0.011). At 1 year, the high-fiber group maintained significantly better bowel scores than the habitual-fiber group (+0.1 ± 14.5 vs -8.4 ± 13.3; P = 0.004).
Wedlake L, Shaw C, McNair H, et al. Am J Clin Nutr, 2017. PMID 28679552
2015 / Randomized controlled trial
In an open-label trial, 113 men with prostate cancer were randomized to consume six daily cups of brewed green tea, black tea, or water before radical prostatectomy; 93 finished the intervention. Proliferation, apoptosis, and tissue oxidation markers did not differ across groups. Green tea significantly decreased prostate tissue nuclear NFκB (p = 0.013), reduced urinary 8OHdG (p = 0.03), and modestly lowered serum PSA (p = 0.04) relative to control.
Henning SM, Wang P, Said JW, et al. Prostate, 2015. PMID 25545744
2015 / Phase I-II clinical trial
A phase I-II trial examined high-dose intravenous vitamin C added to chemotherapy in 14 patients with advanced cancer and limited treatment response expectations. The infusions were generally well tolerated, with only transient adverse events recorded. Pharmacokinetic analyses indicated higher tissue uptake of vitamin C following chemotherapy without increases in urinary oxalic acid. Three patients exhibited brief periods of stable disease and functional improvement.
Hoffer LJ, Robitaille L, Zakarian R, et al. PLoS One, 2015. PMID 25848948
2015 / Randomized controlled trial
In a randomized, placebo-controlled trial, 97 men with high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation (ASAP), or both received either 400 mg daily EGCG from green tea catechins or a placebo for one year. One-year prostate cancer incidence did not differ significantly between arms (5 of 49 with catechins vs 9 of 48 with placebo, p = 0.25). The catechin group showed reduced serum PSA (-0.87 ng/mL, 95% CI -1.66 to -0.09).
Kumar NB, Pow-Sang J, Egan KM, et al. Cancer Prev Res (Phila), 2015. PMID 25873370
2015 / Randomized controlled trial
Sixty men with premalignant prostate lesions received daily lycopene (35 mg), selenium (55 µg), and green tea catechins (600 mg), or placebo for 6 months. At re-biopsy in 53 men, prostate cancer was diagnosed in 10 men in the supplement group versus 3 in the placebo group (p = 0.053). Supplementation was also associated with altered microRNA expression linked to cancer progression, while PSA levels and symptom scores showed no significant differences.
Gontero P, Marra G, Soria F, et al. Prostate, 2015. PMID 25893930
2015 / Two-week dietary exchange trial
Researchers performed supervised 2-week food exchanges where African Americans consumed a high-fibre, low-fat African-style diet and rural Africans consumed a high-fat, low-fibre western-style diet. Compared with usual diets, the dietary switch led to reciprocal changes in mucosal biomarkers of cancer risk, microbiota, and the metabolome. In African Americans, these changes were highlighted by increased saccharolytic fermentation and butyrogenesis alongside suppressed secondary bile acid synthesis.
O'Keefe SJ, Li JV, Lahti L, et al. Nat Commun, 2015. PMID 25919227
2015 / Phase I trial
Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.
Twardowski P, Kanaya N, Frankel P, et al. Cancer, 2015. PMID 25989179
2015 / Randomized, double-blind, placebo-controlled trial
In a randomized trial, 1,075 postmenopausal women took daily green tea extract containing 843 mg epigallocatechin-3-gallate or placebo for one year. Overall adverse event rates were similar between groups (75.6% vs. 72.8%). However, the extract group experienced more nausea (P < 0.001) and significantly more alanine aminotransferase elevations (6.7% vs. 0.7%, P < 0.001), including 1.3% with serious related events.
Dostal AM, Samavat H, Bedell S, et al. Food Chem Toxicol, 2015. PMID 26051348
2015 / Experimental animal study and pilot clinical trial
Cycles of a fasting mimicking diet extended lifespan, stimulated stem cell regeneration upon re-feeding, reduced visceral fat, decreased cancer incidence, and improved cognitive performance in mice. In a pilot clinical trial, three cycles of the fasting mimicking diet decreased risk factors and biomarkers associated with aging, diabetes, cardiovascular disease, and cancer without causing major adverse effects.
Brandhorst S, Choi IY, Wei M, et al. Cell Metab, 2015. PMID 26094889
2015 / Randomized controlled trial
In a randomized trial with 183 men showing rising PSA levels after prostate cancer therapy, subjects received pomegranate extract (n=102), placebo (n=64), or juice (n=17). Median PSA doubling time increased across all groups: 11.1 to 15.6 months with placebo, 12.9 to 14.5 months with extract, and 12.7 to 20.3 months with juice, but differences between groups were not statistically significant (P>0.05).
Pantuck AJ, Pettaway CA, Dreicer R, et al. Prostate Cancer Prostatic Dis, 2015. PMID 26169045
2015 / Randomized crossover trial
A crossover trial randomized 22 healthy adults to consume approximately 50 g of palm dates or a control carbohydrate supplement daily for 21 days separated by a 14-day washout. Date intake did not alter short-chain fatty acids or selected bacterial groups. However, date intake significantly increased bowel movement frequency (P<0.01; n=21), reduced stool ammonia (P<0.05; n=21), and lowered fecal water genotoxicity compared to control (P<0.01; n=21).
Eid N, Osmanova H, Natchez C, et al. Br J Nutr, 2015. PMID 26428278
2015 / Randomized controlled trial
Thirteen women with HER2-negative stage II or III breast cancer receiving chemotherapy were randomized to fast for 24 hours before and after infusion or follow standard dietary guidelines. Seven days post-chemotherapy, mean erythrocyte counts (P = 0.007, 95% CI 0.106 to 0.638) and thrombocyte counts (P = 0.00007, 95% CI 38.7 to 104) were significantly higher in the fasting group. Fasting also prevented an acute post-chemotherapy rise in peripheral blood mononuclear cell DNA damage.
de Groot S, Vreeswijk MP, Welters MJ, et al. BMC Cancer, 2015. PMID 26438237
2015 / Randomized controlled trial
A double-blind trial randomized 56 breast cancer patients receiving doxorubicin into groups consuming 100-160 g/day or 30-40 g/day of fresh yellow onion for eight weeks. Participants consuming the higher amount of onion showed significant reductions in carcinoembryonic antigen, cancer antigen-125, and alkaline phosphatase levels compared to the low-onion group (P < 0.05).
Jafarpour-Sadegh F, Montazeri V, Adili A, et al. Asian Pac J Cancer Prev, 2015. PMID 26625755
2014 / Randomized double-blind placebo-controlled trial
Ninety-eight women with persistent oncogenic HPV and cervical intraepithelial neoplasia received either daily Polyphenon E or placebo for four months. Complete clearance occurred in 17.1% (7 women) of the intervention group and 14.6% (6 women) receiving placebo, showing no significant difference between treatments. Furthermore, disease progression was observed in 14.6% of women taking the extract compared to 7.7% of those given placebo.
Garcia FA, Cornelison T, Nuño T, et al. Gynecol Oncol, 2014. PMID 24388920
2014 / Randomized controlled trial
A randomized trial assigned 130 breast cancer patients undergoing mastectomy to receive 10 mg oral beta-glucan capsules twice daily or placebo for 10 days. Beta-glucan significantly lowered daily drainage volumes between days 2 and 8 and shortened mean drain removal time to 7.16 days compared to 8.59 days with placebo (p < 0.001). Interleukin-6 and tumor necrosis factor-alpha levels on days 1 and 2 were also significantly lower with beta-glucan (p < 0.001).
Yenidogan E, Akgul GG, Gulcelik MA, et al. Adv Ther, 2014. PMID 24421054
2014 / Case-cohort study within a randomized trial
In a case-cohort analysis of the SELECT trial, researchers evaluated whether baseline toenail selenium modified the effects of selenium and vitamin E on prostate cancer (PCa) risk. Selenium supplementation did not affect risk in men with low baseline selenium (<60th percentile) but increased high-grade PCa risk by 91% (P = .007) in men with higher baseline selenium. Vitamin E alone had no effect in men with high baseline selenium (≥40th percentile) but increased risks of total (63%, P = .02) and high-grade PCa (111%, P = .008) among men with lower baseline selenium status.
Kristal AR, Darke AK, Morris JS, et al. J Natl Cancer Inst, 2014. PMID 24563519
2014 / Randomized controlled trial
A randomized trial tested a capsule containing pomegranate, green tea, broccoli, and turmeric versus placebo for 6 months in 199 men with localized prostate cancer. The median increase in prostate-specific antigen was significantly lower in the supplement group at 14.7% (95% CI, 3.4-36.7%) compared to 78.5% in the placebo group (95% CI, 48.1-115.5%; P = 0.0008). Significantly fewer supplemented participants chose to exit surveillance (8.2% vs. 27.7%, P = 0.014).
Thomas R, Williams M, Sharma H, et al. Prostate Cancer Prostatic Dis, 2014. PMID 24614693
2014 / Randomized controlled trial
In a 12-week randomized trial of 291 adults in China, drinking a daily broccoli sprout beverage significantly increased urinary excretion of glutathione conjugates of benzene by 61% and acrolein by 23% compared with placebo (P <= 0.01). Excretion of crotonaldehyde conjugates remained unchanged. Urinary sulforaphane metabolites showed that bioavailability was sustained throughout the 12-week daily dosing regimen.
Egner PA, Chen JG, Zarth AT, et al. Cancer Prev Res (Phila), 2014. PMID 24913818